Core Insights - ResMed reported strong revenue growth of 11% in the December quarter, with a GAAP EPS increase of 16% on revenue of $1.42 billion, driven by device and mask sales growth across various regions [2][3][6] Revenue Growth - In Canada and Latin America, constant-currency device sales increased by 8% and masks and other sales rose by 16%, attributed to resupply growth and new patient setups, along with revenue from the VirtuOx acquisition [1] - Excluding the Residential Care Software (RCS) business, sales in the U.S., Canada, and Latin America rose by 11% (6% on a constant currency basis) [2] - Globally, device sales increased by 7% and masks and other sales grew by 14% on a constant currency basis [2] Margin Expansion - The company achieved a gross margin improvement of 110 basis points year-over-year, with an operating margin increase to 36.3% [6][11] - Management expects fiscal 2026 gross margin to be between 62% and 63%, influenced by currency movements [8] Capital Returns - ResMed declared a quarterly dividend of $0.60 per share and repurchased approximately $175 million worth of shares, increasing planned buybacks to over $600 million for fiscal 2026 [5][19][20] Product Development and Innovation - The company is advancing new products, including the FDA-cleared AI recommender Comfort Match and the F30i fabric mask line, with positive feedback from early users [5][12][13] - Management highlighted the importance of GLP-1 medications as a demand tailwind, noting that patients on both GLP-1 and CPAP are 10-11% more likely to start therapy [6][15][16] Operating Expenses - Operating expenses rose, with SG&A increasing by 15% on a headline basis, driven by employee-related expenses and marketing investments [9] - R&D expenses increased by 12% on a headline basis, with expectations to maintain R&D at 6% to 7% of revenue for fiscal 2026 [10] Cash Flow and Financial Position - Cash flow from operations was reported at $340 million, with capital expenditures of $29 million, leaving the company with $1.4 billion in cash and $753 million in net cash [18]

Financial Data and Key Metrics Changes - The company reported an 11% headline revenue growth and a 9% growth on a constant currency basis for the second quarter of fiscal year 2026, with GAAP EPS growth of 16% [4][28] - Gross margin increased by 110 basis points year-over-year and by 30 basis points sequentially, reaching 62%-63% for fiscal year 2026 [30][31] - Operating profits increased by 19%, with an operating margin improvement to 36.3% compared to 34% in the prior year [32] Business Line Data and Key Metrics Changes - Global devices revenue experienced high single-digit growth, while masks, accessories, and other revenue saw double-digit growth [4][5] - Residential care software revenue increased by 5% on a constant currency basis, driven by strong performance from the Medifox Dan software vertical [30] Market Data and Key Metrics Changes - Sales in the U.S., Canada, and Latin America increased by 11%, with a 6% increase on a constant currency basis [29] - In Europe, Asia, and other regions, device sales increased by 5% on a constant currency basis, while masks and other sales increased by 8% [29] Company Strategy and Development Direction - The company aims to build a leading digital health ecosystem encompassing sleep health, breathing health, and healthcare technology delivered in the home [8] - Continued focus on operational excellence and innovation, with a commitment to R&D investments of 6%-7% of revenues and SG&A investments of 19%-20% [26][31] - The company is expanding its digital sleep health concierge capabilities and enhancing its manufacturing footprint to improve delivery efficiency [10][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in re-accelerating growth in Europe, Asia, and the rest of the world, with expectations of sustainable high single-digit growth in the residential care software business by fiscal year 2027 [5][6] - The company is closely monitoring the global trade environment and regulatory landscape, with positive implications from recent developments in competitive bidding programs [21][23] Other Important Information - The company returned $263 million to shareholders through dividends and $175 million in share repurchases during the quarter, with plans to increase share repurchases to over $600 million for fiscal year 2026 [34][26] - The launch of new AI-enabled products, such as Comfort Match, is expected to enhance patient adherence to therapy [12][19] Q&A Session Summary Question: Strong US mask number and impact of Virtuox - Management confirmed that the strong growth in masks includes contributions from Virtuox, but even without it, there was solid double-digit growth in masks and accessories [36][38] Question: Update on GLP-1 landscape and its impact - Management noted a 10%-11% higher start rate for CPAP therapy among patients with GLP-1 prescriptions, indicating a motivated patient group [39][41] Question: SG&A growth ahead of revenue growth - Management explained that the SG&A growth includes impacts from the Virtuox acquisition and promotional activities, but underlying growth is tracking closely with revenue [43] Question: Impact on patient funnel stages - Management highlighted significant progress in the top of the funnel due to increased awareness from Big Pharma and tech, while focusing on scaling home sleep apnea testing [45][47] Question: Potential return of Philips to the US market - Management expressed confidence in competing effectively against Philips, noting that they have been performing well in various markets despite Philips' presence [60][62]